• Explore /
  • Poster
  • / Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.

Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.

Abstract Poster

Authors

null

Cornelius F. Waller

University of Freiburg Medical Center, Freiburg, Germany

Cornelius F. Waller , Aleksei Manikhas , Eduardo J. Pennella , Igor Bondarenko , Guzel Mukhametshina , Maria Luisa Abesanis Tiambeng , Charuwan Akewanlop , Ihor Vynnychenko , Virote Sriuranpong , Sirshendu Ray , Miguel Hernandez-Bronchud , Jay Herson , Joseph D. Parra , Gia Nemsadze , Unmesh Gopalakrishnan , Subramanian Loganathan , Rafael Muniz , Abhijit Barve , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT02472964

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1021)

DOI

10.1200/JCO.2019.37.15_suppl.1021

Abstract #

1021

Poster Bd #

102

Abstract Disclosures

Similar Posters

First Author: Joohyuk Sohn

First Author: Xiuwen Guan

First Author: Brian M. Slomovitz

First Author: Zhonghui Ou